Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.84
-0.0200-0.52%
Pre-market: 3.900.0600+1.56%07:11 EDT
Volume:786.21K
Turnover:3.01M
Market Cap:120.15M
PE:-0.93
High:3.90
Open:3.90
Low:3.75
Close:3.86
52wk High:50.40
52wk Low:3.60
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.97
T/O Rate:4.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.55
PE(LYR):-1.35

Loading ...

Revive Therapeutics Moves to Build Global Bucillamine Franchise in Biodefence and Rare Diseases

TIPRANKS
·
Sep 16

Allarity Therapeutics is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Sep 16

Alterity Therapeutics Seeks Quotation for New ASX Shares

TIPRANKS
·
Sep 16

Top Oruka Therapeutics Insiders Quietly Cash Out in Major Stock Moves

TIPRANKS
·
Sep 16

Decoy Therapeutics Shareholders Approve Key Capital Structure Changes

TIPRANKS
·
Sep 16

Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang

MT Newswires Live
·
Sep 16

Tempest Therapeutics Announces New Private Warrant Financing

TIPRANKS
·
Sep 16

Coya Therapeutics Price Target Maintained with a $16.00/Share by BTIG

Dow Jones
·
Sep 16

Summit Therapeutics Highlights Positive Ivonescimab Phase III Survival Data

TIPRANKS
·
Sep 15

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

GlobeNewswire
·
Sep 15

Neurizon Therapeutics Redeems 1 Million Convertible Notes Without Conversion

TIPRANKS
·
Sep 15

Immunology-Focused Biotech Electra Therapeutics Sets IPO Price Range at $14-$16 Per Share, Eyeing $325 Million Raise

Stock News
·
Sep 15

Prescient Therapeutics Extends Securities Purchase Plan Deadline

TIPRANKS
·
Sep 15

Amplia Therapeutics, ANZGOG Finalize Protocol for Phase Two Ovarian Cancer Trial; Shares Up 4%

MT Newswires Live
·
Sep 15

Quince Therapeutics Divests Italian Subsidiary, Refocuses Strategy

TIPRANKS
·
Sep 15

Agomab Therapeutics Reports Positive Phase 1 Data for Lung Disease Drug

Dow Jones
·
Sep 15

Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit

MT Newswires Live
·
Sep 15

Turn Therapeutics Price Target Announced at $10.00/Share by WBB Securities

Dow Jones
·
Sep 15

Larimar Therapeutics assumed with an Outperform at Leerink

TIPRANKS
·
Sep 14

Summit Therapeutics Showcases Promising Ivonescimab Survival Data

TIPRANKS
·
Sep 14